A Phase II Neoadjuvant Trial of Sunitinib Malate (SU011248) Plus Hormonal Ablation for Patients Who Have High Risk Localized Prostate Cancer and Will Undergo Prostatectomy
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 15 Sep 2017
At a glance
- Drugs Sunitinib (Primary) ; Leuprorelin
- Indications Adenocarcinoma; Prostate cancer
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 12 Sep 2017 Planned primary completion date changed from 1 Dec 2018 to 1 May 2019.
- 12 Sep 2016 Planned primary completion date changed from 1 Dec 2017 to 1 Dec 2018.